P
Precision for Medicine
Discovery, development, clinical trial work, and implementation of biomarkers essential for targeting patients more precisely and effectively
About Precision for Medicine
Precision For Medicine is a global clinical research organization (CRO) that specializes in integrating advanced technologies to maximize insights into patient biology. The company serves life sciences clients, including pharmaceutical and biotechnology companies, by supporting clinical trials at every stage from first-in-human to regulatory approval. Precision For Medicine operates in the precision medicine market, focusing on oncology, cell and gene therapy, and rare and orphan diseases. The business model revolves around offering comprehensive clinical trial services, specialty lab services, and data sciences to enhance the speed, cost-efficiency, and success rate of bringing life-changing therapies to patients. Revenue is generated through contracts with life sciences companies for conducting clinical trials, providing biostatistical support, and offering specialized laboratory services.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Bethesda, United States
- Employees
- 1,976
- Open positions
- 364
- Dealroom signal
- 50.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Data Analytics, Biotechnology, Medical & Healthcare, Core AI, Precision Medicine, Disease, Arts & Culture, Clinical Trials, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech
- Business model
- SaaS
- Investment activity
- 4 companies, latest May 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Dec 2015 | $75M | $525M | TPG Growth | — |
| GROWTH EQUITY VCOther financing | Apr 2013 | $150M | — | Ethan Leder · J.H. Whitney & Co · Mark Clein · Oak Investment | — |
Growth signals
Latest recorded traffic for Precision for Medicine is 29K monthly website visits, down 32.6% over the last three months. Precision for Medicine's team grew 4.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AlgoricsFramingham, United StatesAlgorics helps bio-pharma companies and CROs conduct better and faster clinical trials with real time clinical data insights
$1.2Mvaluation
Baseline ControlsRaleigh, United States
→
EpiontisBerlin, GermanyIdentifies and quantifies any immune cell type with accuracy and technical ease
→
Applied ImmunologyRedwood City, United StatesProvider of contract research laboratory services to support the development of biological therapeutics
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
J.H. Whitney & Co
Oak Investment
Ethan Leder- MCMark Clein
TPG Growth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Precision for Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Precision for Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.